SightfileU.S. market data from official filings

EIKON THERAPEUTICS INC (EIKN)

Name: EIKON THERAPEUTICS INC (EIKN) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001861123 · EDGAR filings · Updated 2026-06-15

EIKON THERAPEUTICS INC (EIKN) has reported institutional ownership of 43.9%, with 52 institutional managers holding positions valued at $251.2M per the latest 13F reporting period.

Institutional ownership

43.9%

Institutional managers

Reported 13F value

$251.2M

Insider activity

37 trans.

$51.1M net buying

Latest updates

2026-06-15 — Initial insider ownership filed (Form 3)
2026-06-10 — Current report (8-K) filed
2026-06-01 — Current report (8-K) filed
2026-05-15 — SCHEDULE 13G filed
2026-05-13 — SCHEDULE 13G filed
2026-05-11 — Quarterly report (10-Q) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, EIKON THERAPEUTICS INC has 52 institutional holders and institutional ownership of 43.9%.

Insider activity

Insiders reported 37 transactions (9 buys, 0 sells) across 7 reporting insiders, with a net reported value of $51.1M.

Related companies

ORTHOPEDIATRICS CORP (KIDS) · SURROZEN INC (SRZN) · PALISADE BIO INC (PALI) · Immix Biopharma Inc (IMMX) · AGOMAB THERAPEUTICS NV (AGMB) · PROTARA THERAPEUTICS INC (TARA)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-15.